Hazel R. Evans, J. Mark Sutton, Daniel E. Holloway, Joanne Ayriss, Clifford C. Shone, K. Ravi Acharya,
... active (18Foster R. Hu K.-Q. Lu Y. Nolan K.M. Thissen J. Settleman J. Mol. Cell. Biol. 1996; 16: 2689-2699Crossref PubMed Scopus (246) Google Scholar), and they are, therefore, speculated to reduce RhoA activity by sequestering the exchange factors required to activate it (10Wilde C. Chhatwal G.S. Schmalzing G. Aktories K. Just I. J. Biol. Chem. 2001; 276: 9537-9542Abstract Full Text Full Text PDF PubMed Scopus ( ...
Tópico(s): Antimicrobial Resistance in Staphylococcus
2003 - Elsevier BV | Journal of Biological Chemistry
Christian Wilde, G.S. Chhatwal, Günther Schmalzing, Klaus Aktories, Ingo Just,
... workers (18Foster R. Hu K.-Q. Lu Y. Nolan K.M. Thissen J. Settleman J. Mol. Cell. ... workers (18Foster R. Hu K.-Q. Lu Y. Nolan K.M. Thissen J. Settleman J. Mol. Cell. ... GTP (18Foster R. Hu K.-Q. Lu Y. Nolan K.M. Thissen J. Settleman J. Mol. Cell. ... acids (18Foster R. Hu K.-Q. Lu Y. Nolan K.M. Thissen J. Settleman J. Mol. Cell. ... activity (18Foster R. Hu K.-Q. Lu Y. Nolan K.M. Thissen J. Settleman J. Mol. Cell. ...
Tópico(s): Antimicrobial Resistance in Staphylococcus
2001 - Elsevier BV | Journal of Biological Chemistry
Kyomi J. Igarashi, Iwo Kuciński, Yan Yi Chan, Tze-Kai Tan, Hwei Minn Khoo, David Kealy, Joydeep Bhadury, Ian Hsu, Pui Yan Ho, Kouta Niizuma, John W. Hickey, Garry P. Nolan, Katherine S. Bridge, Agnieszka Czechowicz, Berthold Göttgens, Hiromitsu Nakauchi, Adam C. Wilkinson,
Hematopoietic stem cells (HSCs) are a rare type of hematopoietic cell that can entirely reconstitute the blood and immune system after transplantation. Allogeneic HSC transplantation (HSCT) is used clinically as a curative therapy for a range of hematolymphoid diseases; however, it remains a high-risk therapy because of its potential side effects, including poor graft function and graft-versus-host disease (GVHD). Ex vivo HSC expansion has been suggested as an approach to improve hematopoietic reconstitution ...
Tópico(s): T-cell and B-cell Immunology
2023 - Elsevier BV | Blood Advances
Craig A. Portell, Nolan A. Wages, Brad S. Kahl, Lihua E. Budde, Robert W. Chen, Jonathon B. Cohen, Nikole Varhegyi, Gina R. Petroni, Michael E. Williams,
Relapsed Mantle cell lymphoma (MCL) is often treated with Bruton's tyrosine kinase inhibitors (BTKi); however, post-BTKi relapse can be challenging. Adding venetoclax (VEN) to ibrutinib (IBR) has shown synergy in preclinical MCL models. Prior MCL studies of the combination show promising efficacy but have conducted limited dose finding. We sought to identify the optimal dosing combination, based on efficacy and toxicity, utilizing a continual reassessment method of 6 combinations of IBR (280 mg, 420 ...
Tópico(s): Chronic Myeloid Leukemia Treatments
2021 - Elsevier BV | Blood Advances
B. Nolan, Anna Klukowska, Amy D. Shapiro, Antoine Rauch, Michael Recht, Margaret V. Ragni, Julie Curtin, Sriya Gunawardena, Sutirtha Mukhopadhyay, Deepthi Jayawardene, Bent Winding, Kathelijn Fischer, Raina Liesner,
Abstract PUPs B-LONG evaluated the safety and efficacy of recombinant factor IX Fc fusion protein (rFIXFc) in previously untreated patients (PUPs) with hemophilia B. In this open-label, phase 3 study, male PUPs (age <18 years) with hemophilia B (≤2 IU/dL of endogenous factor IX [FIX]) were to receive treatment with rFIXFc. Primary end point was occurrence of inhibitor development, with a secondary end point of annualized bleed rate (ABR). Of 33 patients who received ≥1 dose of rFIXFc, 26 (79%) were age & ...
Tópico(s): Platelet Disorders and Treatments
2021 - Elsevier BV | Blood Advances
Michelle Lavin, Sonia Águila, Niall Dalton, Margaret Nolan, Mary Byrne, Kevin M. Ryan, Barry White, Niamh O’Connell, Jamie M. O’Sullivan, Jorge Di Paola, Paula James, James S. O’Donnell,
Key Points BATs differ significantly in sensitivity for detecting menorrhagia in women with low VWF. Despite pregnancy-related increases in plasma VWF levels, significant PPH may occur in women with low VWF.
Tópico(s): Blood Coagulation and Thrombosis Mechanisms
2018 - Elsevier BV | Blood Advances
Dearbhla Doherty, Michelle Lavin, Mary Byrne, Margaret Nolan, Jamie M. O’Sullivan, Kevin M. Ryan, Niamh O’Connell, Sandra L. Haberichter, Pamela A. Christopherson, Jorge Di Paola, Paula James, James S. O’Donnell,
Increased von Willebrand factor (VWF) clearance plays a key role in the pathogenesis of type 1 and type 2 von Willebrand disease (VWD). However, the pathological mechanisms involved in patients with mild to moderate reductions in plasma VWF:Ag (range, 30-50 IU/dL; low VWF) remain poorly understood. In this study, we investigated the hypothesis that enhanced VWF clearance may contribute to the pathobiology of low VWF. Patients with low VWF were recruited to the LoVIC study after ethics approval and ...
Tópico(s): Blood disorders and treatments
2022 - Elsevier BV | Blood Advances
Kristen E. Howell, Mariam Kayle, Matthew P. Smeltzer, Val Nolan, Joacy G. Mathias, Marquita Nelson, Sheila Anderson, Jerlym S. Porter, Nirmish Shah, Jane S. Hankins,
Guidelines recommend transfer to adult health care within 6 months of completing pediatric care; however, this has not been studied in sickle cell disease (SCD). We hypothesized that longer transfer gaps are associated with increased resource utilization. Transfer gaps were defined as the time between the last pediatric and first adult visits. We estimated the association between varying transfer gaps and the rates of inpatient, emergency department (ED), and outpatient visits, using negative binomial ...
Tópico(s): Emergency and Acute Care Studies
2024 - Elsevier BV | Blood Advances
Ashley C. Kramer, Yuliana Astuti, Alexis K. Elfstrum, Michael Jonathan Lehrke, Jakub Tolar, Bruce R. Blazar, Amanda L. Blake, Mandy Taisto, Justin W. Furcich, Erin E. Nolan, Wilaiwan Durose, Beau R. Webber, Athena Geisness, David K. Wood, Troy C. Lund,
Hematopoietic cell homing after hematopoietic cell transplant (HCT) is governed by several pathways involving marrow niche cells that are evoked after pre-HCT conditioning. To understand the factors that play a role in homing, we performed expression analysis on the zebrafish marrow niche cells following conditioning. We determined that the non-collagenous protein extracellular matrix related protein dermatopontin (Dpt) was upregulated seven-fold in response to irradiation. Studies in mice revealed ...
Tópico(s): Virus-based gene therapy research
2021 - Elsevier BV | Blood Advances
Produção Nacional
Revisado por pares
Amy D. Shapiro, Roshni Kulkarni, Margaret V. Ragni, Hérvè Chambost, Johnny Mahlangu, Johannes Oldenburg, B. Nolan, Margareth C. Ozelo, Meredith C. Foster, Annemieke Willemze, Christopher Barnowski, Nisha Jain, Bent Winding, Jennifer Dumont, Stefan Lethagen, Chris Barnes, John Pasi,
Abstract Long-term efficacy and safety of the extended half-life recombinant factor IX Fc fusion protein (rFIXFc) has been established among previously treated patients with severe hemophilia B in 2 phase 3 trials (B-LONG [#NCT01027364] and Kids B-LONG [#NCT01440946]) and a long-term extension study (B-YOND [#NCT01425723]). In this study, we report post hoc analyses of pooled longitudinal data for up to 6.5 years for rFIXFc prophylaxis. In the B-LONG study, subjects ≥12 years received weekly dose-adjusted ...
Tópico(s): Blood Coagulation and Thrombosis Mechanisms
2023 - Elsevier BV | Blood Advances
Erin E. Nolan, Wilaiwan Durose, Leyla Taghizadeh, Carina J. King, Ashish O. Gupta, Paul J. Orchard, Maggie Lorentson, Kai Braaten, Justin W. Furcich, Troy C. Lund,
Tópico(s): Pharmacological Effects and Toxicity Studies
2023 - Elsevier BV | Blood Advances